BioCentury | Dec 9, 2019
Company News

With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race

...RET Inhibitor ”). Meanwhile, AbbVie gained rights to Imbruvica via its $22 billion acquisition of Pharmacyclics Inc....
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...a newly created position. Northcott served as chief commercial officer of AbbVie Inc. (NYSE:ABBV) unit Pharmacyclics Inc....
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...Shire plc, a $5.8 billion acquisition of Stemcentrx Inc. and a $21 billion acquisition of Pharmacyclics Inc....
BioCentury | Feb 1, 2019
Company News

AbbVie loses $8B in market cap on steeper Humira erosion

...Richard Gonzalez said while the company’s largest deal to date has been the acquisition of Pharmacyclics Inc....
BioCentury | Jan 25, 2019
Company News

AbbVie loses $8B in market cap on steeper Humira erosion

...Richard Gonzalez said while the company’s largest deal to date has been the acquisition of Pharmacyclics Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...plc (ACT); Forest Laboratories Inc. (FRX); Sanofi (Euronext:SAN; NYSE:SNY); Genzyme Corp. (GENZ); AbbVie Inc. (NYSE:ABBV); Pharmacyclics Inc....
BioCentury | Dec 21, 2018
Financial News

Summit proposes $25M private placement

...of 78.1 million ADSs at $1.60 to Duggan, who is former chairman and CEO of Pharmacyclics Inc....
BioCentury | Apr 6, 2018
Finance

Picking season

...company, even if the acquisition is costly. AbbVie Inc.’s $21 billion takeout of oncology play Pharmacyclics Inc....
...is a case in point. The pharma’s stock price had more than doubled since the Pharmacyclics...
BioCentury | Mar 23, 2018
Financial News

CASI raises $50M in private placement

...IDG-Accel China Growth Fund III and Robert Duggan. Duggan is former chairman and CEO of Pharmacyclics Inc....
BioCentury | Oct 6, 2017
Company News

Management tracks: Impel, InGeneron

...was chief compliance officer and associate general counsel, head of healthcare and regulatory law at Pharmacyclics Inc....
Items per page:
1 - 10 of 542
BioCentury | Dec 9, 2019
Company News

With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race

...RET Inhibitor ”). Meanwhile, AbbVie gained rights to Imbruvica via its $22 billion acquisition of Pharmacyclics Inc....
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...a newly created position. Northcott served as chief commercial officer of AbbVie Inc. (NYSE:ABBV) unit Pharmacyclics Inc....
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...Shire plc, a $5.8 billion acquisition of Stemcentrx Inc. and a $21 billion acquisition of Pharmacyclics Inc....
BioCentury | Feb 1, 2019
Company News

AbbVie loses $8B in market cap on steeper Humira erosion

...Richard Gonzalez said while the company’s largest deal to date has been the acquisition of Pharmacyclics Inc....
BioCentury | Jan 25, 2019
Company News

AbbVie loses $8B in market cap on steeper Humira erosion

...Richard Gonzalez said while the company’s largest deal to date has been the acquisition of Pharmacyclics Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...plc (ACT); Forest Laboratories Inc. (FRX); Sanofi (Euronext:SAN; NYSE:SNY); Genzyme Corp. (GENZ); AbbVie Inc. (NYSE:ABBV); Pharmacyclics Inc....
BioCentury | Dec 21, 2018
Financial News

Summit proposes $25M private placement

...of 78.1 million ADSs at $1.60 to Duggan, who is former chairman and CEO of Pharmacyclics Inc....
BioCentury | Apr 6, 2018
Finance

Picking season

...company, even if the acquisition is costly. AbbVie Inc.’s $21 billion takeout of oncology play Pharmacyclics Inc....
...is a case in point. The pharma’s stock price had more than doubled since the Pharmacyclics...
BioCentury | Mar 23, 2018
Financial News

CASI raises $50M in private placement

...IDG-Accel China Growth Fund III and Robert Duggan. Duggan is former chairman and CEO of Pharmacyclics Inc....
BioCentury | Oct 6, 2017
Company News

Management tracks: Impel, InGeneron

...was chief compliance officer and associate general counsel, head of healthcare and regulatory law at Pharmacyclics Inc....
Items per page:
1 - 10 of 542